Business Wire

H.I.G. Europe to Acquire Meyra Group and Alu Rehab to Form Leading Mobility Equipment Manufacturer in Europe

Share

H.I.G. Capital ("H.I.G."), a leading global private equity investment firm with over EUR 31 billion of equity capital under management, is pleased to announce that an affiliate has signed definitive agreements to acquire Meyra Group S.A. and Alu Rehab A/S. With the support of H.I.G., both companies will combine to form a new leading mobility equipment manufacturer in Europe. The transaction is subject to clearing by the relevant antitrust authorities with closing anticipated by end of 2019.

Meyra Group S.A. (“Meyra”) designs, manufactures and sells active and e-powered wheelchairs, rehabilitation equipment and orthopedics. The company is among the market leaders within the segment of premium, technologically advanced wheelchairs for active users and sells its products worldwide under the iconic “Meyra” brand since 1936. With manufacturing, assembly and distribution sites in Germany and Poland, Meyra has approximately 600 employees and is expected to generate more than EUR 80 million in sales in 2019.

Alu Rehab A/S (“Alu Rehab”) is a comfort wheelchair specialist, which was established in 1989 and sells its products under the well-known “Netti” brand. The company’s multifunctional comfort wheelchairs, specialized seating systems and equipment are designed to support customers in their daily lives by tailoring solutions to individual needs. Alu Rehab has manufacturing, assembly and distribution facilities in Norway, Denmark and China and has approximately 120 employees.

Together, both companies will form a new leading mobility equipment manufacturer in Europe and are highly complementary with synergies across the entire value-chain from manufacturing, logistics, assembly to sales and services. The current management teams of both companies will continue to run the group going forward. The combined group will generate over 40% of its sales in the attractive German-speaking healthcare market. Going forward, the new group will further grow in currently underrepresented European countries and selected markets outside Europe, organically and through focused acquisitions.

Michał Perner, President of the Management Board and founding shareholder of Meyra, commented: “Meyra is a very strong brand that has continuously expanded its market position due to superior quality of products and reliable services. We are delighted to partner with H.I.G., who will support us to tap the substantial additional potential of the company and the market we are operating in.”

Kjetil Gausel, CEO of Alu Rehab, commented: “For Alu Rehab, joining with Meyra will open attractive opportunities as we significantly expand our product portfolio and geographic reach. We are convinced that our unique Netti seating system in combination with Meyra’s high-quality active and e-powered wheelchair bases will generate substantial additional demand for the group.”

Holger Kleingarn, Managing Director at H.I.G., commented: “The combination of Meyra and Alu Rehab represents a strong strategic and cultural fit. We look forward to the partnership with Michał, Kjetil and their teams and to supporting them in the group’s international expansion, both organically and by acquisition.”

About H.I.G. Capital

H.I.G. is a leading global private equity and alternative assets investment firm with over EUR 31 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused / value-added approach:

  1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
  2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
  3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of EUR 27 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dr. Holger Kleingarn
Managing Director
hkleingarn@higcapital.com
H.I.G. European Capital Partners GmbH
P: +49 40 41 33 06 100
www.higcapital.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 07:00:00 EET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 03:15:00 EET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 18:59:00 EET | Press release

Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through battle-tested AI Agents at enterprise scale. The new funds will accelerate the adoption of the Torq AI SOC Platform, the only end-to-end solution built on

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye